SpaceNews reports: Blue Origin's New Glenn suffered a malfunction of its second stage on the rocket's third flight April 19, stranding its payload in an unrecoverable "off-nominal" orbit and dealing the company a setback as it seeks to increase its flight rate... AST SpaceMobile had planned to launch 45 to 60 satellites this year for its D2D constellation, but BlueBird 7 is the first to launch since BlueBird 6 launched on an Indian LVM3 rocket in December.
AST SpaceMobile still expects to have 45 satellites in orbit by the end of the year, the article notes. (In an earnings call in March, AST SpaceMobile's CEO had promised they'd soon start "stacking" satellites, "batched in groups of either three, four, six or eight in a single launch.") He'd added that "To support our launch cadence during 2026, we expect the New Glenn booster to be reused every 30 days or less..."

There's some good news there, SpaceNews points out, since today saw the first successful reflight of a New Glenn first stage rocket: The booster, called "Never Tell Me The Odds" by Blue Origin, touched down on the company's landing platform, Jacklyn, in the Atlantic Ocean nearly nine and a half minutes after liftoff. The booster launched NASA's ESCAPADE Mars mission on the NG-2 flight in November. However, the booster reuse on NG-3 was only partial since the stage's biggest component, its BE-4 engines, was new. "With our first refurbished booster we elected to replace all seven engines and test out a few upgrades including a thermal protection system on one of the engine nozzles," Dave Limp, chief executive of Blue Origin, said in an April 13 social media post. "We plan to use the engines we flew for NG-2 on future flights."
The satellite will now be "de-orbited", AST SpaceMobile said in a statement. (They added that "The cost of the satellite is expected to be recovered under the company's insurance policy.")

Thanks to long-time Slashdot reader schwit1 for sharing the news.

After 49 years of space travel, Voyager 1 "is running out of power," reports NPR: The spacecraft runs on a radioisotope thermoelectric generator — a device that converts heat from decaying plutonium into electricity. It carries no solar panels, no rechargeable batteries. Just the slow, steady release of nuclear warmth, which diminishes by about 4 watts each year. After nearly five decades, that decline has become critical.

During a routine maneuver in late February, Voyager 1's power levels fell unexpectedly, bringing the probe dangerously close to triggering an automatic fault-protection shutdown — a self-preservation response that would have forced engineers into a lengthy and risky recovery process. The team needed to act first. On April 17, mission engineers sent a sequence of commands to deactivate the Low-energy Charged Particles experiment, known as the LECP, which is one of Voyager 1's remaining science instruments. The LECP has measured ions, electrons, and cosmic rays originating from both our solar system and the galaxy beyond it, helping scientists map the structure of interstellar space in a way no other instrument could...

Voyager 1 now carries two operational science instruments: one that listens for plasma waves, and one that measures magnetic fields. Engineers believe the latest shutdown could buy the mission roughly another year of breathing room. The team is also developing a more sweeping power conservation plan they informally call "the Big Bang" — a coordinated swap of several powered components all at once, trading older systems for lower-power alternatives. If testing on Voyager 2, planned for May and June 2026, goes well, the same procedure will be attempted on Voyager 1 no sooner than July. If it works, there is even a slim chance the LECP could once more continue to work.

The engineers say they hope to keep at least one instrument operating on each spacecraft into the 2030s. It would leave both still reporting from places no machine has ever gone before.111
Voyager 1 is now 15 billion miles from Earth, the article points out. (Radio signals take 23 hours to arrive...)

Thanks to long-time Slashdot reader fahrbot-bot for sharing the article.

NBC News reports on a 16-person clinical trial of "personalized messenger RNA vaccines" which use the immune system to fight cancer cells. "The goal is not to eliminate existing tumors, but instead to stamp out lingering, undetected cancer cells, and later any new cells that form before they can cause a recurrence." Patients still have surgery to remove tumors. After that, the mRNA vaccines are personalized for each individual using genetic material taken from their unique tumor cells. In the clinical trial, after getting the vaccine, the patients also received chemotherapy, which is standard post-op treatment for operable pancreatic cancer... [The article notes that less than 13% of people diagnosed with pancreatic cancer live for more than five years, making it "one of the deadliest cancers."]

[E]xperts have long believed that people with pancreatic cancer could not generate an immune response against tumors. But after nine doses of the personalized vaccine, [clinical trial participant Donna] Gustafson is one of eight people in the 16-person Phase 1 trial who did just that, producing an army of immune cells called T cells that seek out and destroy tumor cells... [Dr. Vinod Balachandran, a vaccine center director who is leading the trial, said] it was unclear whether the immune response would last and lead to the patients living longer... New data collected during the trial's six-year follow-up period shows that it may. Those findings will be presented Monday at the American Association for Cancer Research's annual meeting in San Diego. Six years after treatment, Gustafson and six others who responded to the treatment are still alive...

More research is still needed. Genentech and BioNTech, the two drugmakers behind the vaccine, have already launched a larger Phase 2 clinical trial... Another team is working on an off-the-shelf vaccine that targets a protein called KRAS that is present in as many as 90% of pancreatic cancers. In a small, early trial, about 85% of the participants mounted an immune response to the protein.